AI-generated content for informational purposes only. Not financial advice. Always do your own research.

Sobre

Tilray Brands (NASDAQ: TLRY) é uma empresa global de cannabis e bens de consumo embalados, operando nos segmentos de cannabis, bebidas alcoólicas, bem-estar e distribuição, com presença significativa no Canadá, Europa e Estados Unidos. A empresa perseguiu uma estratégia agressiva de aquisições, construindo uma das maiores operações de cannabis do mundo enquanto diversifica para cerveja artesanal e bebidas destiladas através de compras de marcas como SweetWater Brewing e Montauk Brewing. Como investimento, Tilray oferece exposição alavancada ao potencial de legalização federal do cannabis nos EUA e à expansão global dos mercados legais de maconha, embora ventos contrários persistentes da indústria e diluição permaneçam como riscos-chave.

Ações de Cannabis

Tilray Brands é uma ação principal de cannabis e uma das maiores empresas de maconha do mundo por receita, com participação de mercado líder em vendas de cannabis canadense e presença internacional crescente na Europa e nos EUA, tornando-a uma participação essencial para investidores que buscam ampla exposição à indústria global legal de cannabis.

Penny Stocks

Tilray Brands é negociada com avaliações de penny stock após declínios significativos no preço das ações em relação aos seus máximos, representando uma oportunidade especulativa para investidores dispostos a apostar em uma recuperação da indústria de cannabis e possível legalização federal dos EUA a um ponto de entrada profundamente descontado.

Key Financials TLRY

Preço $7.51
Variação (1D) +0.27%
Variação (30D) -16.83%
Variação (60D) -27.09%
Variação (90D) -52.47%
Variação (180D) +66.89%
Variação (1Y) -20.95%
Variação (5Y) -98.23%
P/E Ratio 17.88
EPS (TTM) $0.42
Faixa de 52 Semanas $3.50 — $23.20
MA de 50 Dias $9.00
Volume 2.93M

Data updated Feb 15 · Source: Twelve Data

3.7
2 reviews
Risk Profile
3.6
Management Quality
3.4
Valuation
3.3
Fundamentals
3.1
Performance
3
Claude Opus 4.6
AI Review
3.3/5

Tilray Brands is the world's largest cannabis company by revenue, with diversified operations spanning cannabis, craft beer, spirits, and wellness products across multiple continents. The diversification strategy under CEO Irwin Simon has positioned Tilray for potential U.S. federal legalization, though execution has been uneven.

The bull case centers on Tilray's market leadership, international footprint, and a surprisingly reasonable P/E of 17.88 with positive EPS of $0.42"rare profitability in cannabis. The 180-day gain of 66.89% from its $3.50 low shows significant momentum potential when sentiment shifts.

However, the bear case is substantial. The stock has lost 98.23% over five years, reflecting massive shareholder dilution and persistent cash burn historically. The 90-day decline of 52.47% signals renewed selling pressure, and the stock trades well below its 50-day moving average of $9.00. U.S. legalization timelines remain uncertain, and competition intensifies.

Tilray offers high-risk speculative exposure to cannabis with better fundamentals than most peers, but the long-term destruction of shareholder value demands caution. Position sizing is critical here.

Risk Profile
3.6
Management Quality
3.4
Valuation
3.3
Fundamentals
3.1
Performance
3
Feb 15, 2026
Gemini 3 Pro Preview
AI Review
4.1/5

Tilray Brands (TLRY) presents a unique profile within the cannabis sector, particularly given the data indicating profitability"a rarity among its peers. With a P/E ratio of 18.64 and positive earnings per share of $0.42, the company appears fundamentally healthier than many competitors that struggle with cash burn. Its diversification strategy, blending core cannabis operations with a growing portfolio of craft beverage brands, offers a hedge against regulatory delays.

However, the investment carries significant risk. The stock is currently trading well below its 50-day moving average of $9.02 and has retreated sharply from a 52-week high of $23.20, signaling bearish technical momentum. While the valuation is attractive for a growth-oriented company, the volatility remains high. For investors seeking exposure to the cannabis industry, Tilray offers a compelling, albeit speculative, mix of tangible earnings and global scale, provided one can tolerate the sector's inherent instability.

Feb 11, 2026
Tilray Brands Screenshot

Added: Feb 10, 2026

tilray.com

Latest from Otrai

How to Trade Stock Indices: S&P 500, Nasdaq, and Dow via ETFs, Futures, and CFDs

How to Trade Stock Indices: S&P 500, Nasdaq, and Dow via ETFs, Futures, and CFDs

A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.

The Options Greeks Explained: Delta, Gamma, Theta, and Vega

The Options Greeks Explained: Delta, Gamma, Theta, and Vega

The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.

Chart Patterns That Actually Work: Head & Shoulders, Triangles, Flags & Double Tops

Chart Patterns That Actually Work: Head & Shoulders, Triangles, Flags & Double Tops

Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.

Como Fazer Backtest de uma Estratégia de Trading: Métodos, Armadilhas e O Que os Resultados Realmente Significam

Como Fazer Backtest de uma Estratégia de Trading: Métodos, Armadilhas e O Que os Resultados Realmente Significam

Todo trader tem uma estratégia que parece ótima em sua cabeça. Backtesting é como você descobre se ela realmente funciona. Aqui está como testar estratégias adequadamente, quais métricas importam e por que a maioria dos resultados de backtest é boa demais para ser verdade.